Liver Transplantation for Cardiac Failure from Hereditary Hemorrhagic Telangiectasia

Chawala, Rajesh; Krishnakurup, Jayakrishnan; Khallafi, Hicham; Ambs, Natesha; Muneer, Badar; Pyrsopoulos, Nikolaos

doi:10.14309/00000434-201110002-00821

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two studies were identified by hand-searching in the bibliography of retrieved articles [ 24 , 25 ]. Therefore 45 studies were finally included for analysis [ 10 , 11 , 13 , 15 , 16 , 17 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 ]. The PRISMA flow diagram is depicted in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Bilateral pulmonary embolisms, thrombosis in the right atrial cavity and thrombosis of the right hepatic vein. - BVZ Maggi, 2013 [ 15 ] 2 (all F) 44/64 - 4 HOCF - P1: 5.6/- P2: 10/- - Chawala, 2011 [ 38 ] 1 (F) 44 - 3 * (E, T, V) HOCF Palpitations, dyspnea, and hematochezia 9.1/5.8 - Cag, 2011 [ 39 ] 4 (M/M/F/M) 60/65/40/64 -/ACVRL1/-/- P1: 3 (E, T, V) P2: 3 (T, V, FH) P3: 4 P4: 2 (T, V) P1: VHB induced cirrhosis P2, 3 & 4: HOCF P1: HBV-induced cirrhosis + 2 previous renal transplantation P2: - P3: - P4: HBV-induced cirrhosis P1: -/- P2: 10.5/- P3: 7.9/4.9 P4: 7.8/4.1 No HAE. Medical treatments had been used (not specified).…”

Section: Table A1mentioning

confidence: 99%

See 1 more Smart Citation

Perioperative Complications and Long-Term Follow-Up of Liver Transplantation in Hemorrhagic Hereditary Telangiectasia: Report of Three Cases and Systematic Review

Riera‐Mestre

Cerdà

Guzmán

et al. 2022

JCM

View full text Add to dashboard Cite

The aim was to describe three patients with hemorrhagic hereditary telangiectasia (HHT) requiring liver transplantation (LT) and to perform a systematic review focusing on surgical complications and long-term follow-up. Unrestricted searches of the Medline and Embase databases were performed through February 2022. Forty-five studies were selected including 80 patients plus the three new reported patients, 68 (81.9%) were female and mean age was 50 (27–72) years. Main indications for LT were high-output cardiac failure (n = 40; 48.2%), ischemic cholangitis (n = 19; 22.9%), and a combination of both conditions (n = 13;15.6%). Mean cold ischemic time and red blood cell units transfused during LT were 554 (300–941) minutes and 11.4 (0–88) units, respectively. Complications within 30 days were described in 28 (33.7%) patients, mainly bleeding complications in 13 patients, hepatic artery (HA) thrombosis in four and hepatic vein thrombosis in one. Mean follow-up was 76.4 (1–288) months, and during it, four new patients developed thrombotic complications in HA, HA aneurysm, celiac artery, and the portal–splenic–mesenteric vein. HHT relapse in the transplant allograft was detected in 13 (17.1%) patients after 1–19 years (including two fatal recurrences). Overall mortality was 12%. In conclusion, previous assessment of HA anatomy and hyperdynamic circulatory state could reduce LT complications. The risk of relapse in the hepatic graft supports a multidisciplinary follow-up for HHT patients with LT.

show abstract